|
Jul 28
|
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
|
|
Jul 17
|
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
|
|
Jul 16
|
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
|
|
Jul 15
|
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
|
|
Jul 1
|
Breakeven Is Near for Theravance Biopharma, Inc. (NASDAQ:TBPH)
|
|
Jun 27
|
Viatris gains China approval for Yupelri to treat COPD
|
|
Jun 26
|
Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA
|
|
Jun 3
|
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
|
|
Aug 7
|
Theravance Biopharma Second Quarter 2024 Earnings: Misses Expectations
|
|
Aug 6
|
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
|
|
Jul 24
|
Theravance Biopharma, Inc. (NASDAQ:TBPH): When Will It Breakeven?
|
|
Jul 22
|
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
|
|
Jun 26
|
Here's Why You May Invest in Theravance (TBPH) Stock Now
|
|
Jun 21
|
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
|
|
May 30
|
High Insider Ownership Growth Companies On US Exchange May 2024
|
|
May 14
|
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
|
|
May 13
|
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 13
|
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 9
|
Theravance Biopharma to Participate in an Upcoming Investor Conference
|
|
Apr 29
|
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
|